Siglec-1-targeting single domain antibodies block or enhance pathogen binding to dendritic cells
High-affinity single domain antibodies, (also known as VHHs or Nanobodies) that allo- or orthosterically modulate ligand binding of Siglec-1 are identified and may serve as broad-spectrum pathogen blocking agents.